ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
Analysis limitations: These analyses are exploratory in nature and definitive conclusions should not be drawn.
Efficacy data based on long-term follow-up analysis (median time from ABECMA infusion to data cutoff 27.3 months [range 24.1 to 33.1]; N=100). Data were generally consistent with the primary analysis. See ORR at primary analysis.
BMCA=B-cell maturation antigen; ISS=International Staging System; LCL=lower bound of 95% CI; MM=multiple myeloma; ORR=overall response rate; PI=proteasome inhibitor; TTNT=time to next treatment; UCL=upper bound of 95% CI.